Improvement in Hepatic Encephalopathy with Rifaximin Is Associated with Distinct Changes in the Metagenomic Species in the Saliva and Stool Microbiome and a Reduction in Systemic Inflammation - Results of the Rifsys Randomized Controlled Trial.

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)1462A-1463A
JournalHepatology
Volume68
Issue number6
Publication statusPublished - Dec 2018

Cite this